US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

38.96

-0.2700-0.69%

Volume:279

Turnover:10.81K

Market Cap:7.79M

PE:- -

High:38.96

Open:39.22

Low:38.96

Close:39.23

52wk High:43.01

52wk Low:24.96

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.12

T/O Rate:0.14%

Dividend:0.32

Dividend Rate:0.82%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027

THOMSON REUTERS

Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases

THOMSON REUTERS

Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps

THOMSON REUTERS

Early Backer of Humanoid Robot Startup Sets Sights on Chengdu Brain-Computer Interface Company

New Standards Set to Boost Industry Growth and Consumer Wellbeing

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview

Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share

Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award

Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play

Praxis Advances PRAX-628 Tablet Formulation in Completed Bioavailability Study

Stairway Medical Achieves Key Breakthroughs in Implantable Brain-Computer Interfaces, Helping Multiple High-Level Quadriplegics Return to the Workforce

Good Morning Anhui: Province Records First-Ever Brain-Computer Interface Prescription and Successful Surgery

Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires

Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Multiple New National Standards to Take Effect Starting August 1

Key to Brain-Computer Interfaces Found Through Large AI Models

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IBRN/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":38.9601,"timestamp":1788206400000,"preClose":39.2301,"halted":0,"volume":279,"delay":0,"changeRate":-0.006882470348023664,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.27,"latestTime":"09-01 06:01:31 EDT","open":39.22,"high":38.9601,"low":38.9601,"amount":10811,"amplitude":0,"askPrice":61.94,"askSize":100,"bidPrice":37.05,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":38.9601,"sharesOutstanding":150000,"nav":39.171708,"aum":7834341.6,"dividendRate":0.008201,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.2301,"preClose":38.9601,"latestTime":"16:10 EDT","volume":7,"amount":272.7207,"timestamp":1788207004390,"change":0.27,"changeRate":0.00693,"amplitude":0},"volumeRatio":0.12153684993369444,"impliedVol":0.124,"impliedVolPercentile":0.6693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.12153684993369444,"shares":200000,"dividePrice":0.3195,"high":38.9601,"amplitude":0,"preClose":39.2301,"low":38.9601,"week52Low":24.9594,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":38.9601,"committee":-0.980198,"eps":0,"divideRate":0.008201,"volume":279,"delay":0,"ttmEps":0,"open":39.22,"prevYearClose":32.3193,"prevWeekClose":39.2301,"prevMonthClose":38.9601,"prevQuarterClose":38.8263,"fiveDayClose":39.5297,"twentyDayClose":36.6969,"sixtyDayClose":34.9273},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656753021","title":"Dianthus Therapeutics - Dnth312 Expected to be Phase 1 Ready by Year-End 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2656753021","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656753021?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","DNTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656553079","title":"Dianthus Therapeutics - Dnth312 Targets Inhibition of Ac1s and Baff/April Pathways for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656553079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656553079?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530762","title":"Dianthus Therapeutics - Dnth312 Demonstrates Similar Immunoglobulin Reductions to Povetacicept in Nhps","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656530762?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:09","pubTimestamp":1785841791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN44107X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100243579","title":"Early Backer of Humanoid Robot Startup Sets Sights on Chengdu Brain-Computer Interface Company","url":"https://stock-news.laohu8.com/highlight/detail?id=1100243579","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100243579?lang=en_us&edition=fundamental","pubTime":"2026-08-04 18:14","pubTimestamp":1785838478,"startTime":"0","endTime":"0","summary":"Wabo Technology Co., Ltd. recently announced the completion of its angel round of financing, featuring a notably prestigious lineup of investors. Participants include Vertex Ventures, under...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","688836","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148426331","title":"New Standards Set to Boost Industry Growth and Consumer Wellbeing","url":"https://stock-news.laohu8.com/highlight/detail?id=1148426331","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148426331?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:40","pubTimestamp":1785800457,"startTime":"0","endTime":"0","summary":"Starting August 1, a total of 488 national standards, including 46 mandatory ones and 442 recommended ones, will be implemented, as announced by the State Administration for Market Regulation...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVR","BK4020","RAYS","MNTL","GNSS","IBRN","MAKX","IVRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300056","title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300056","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300056?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:10","pubTimestamp":1785798604,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $98,821.72David Joseph Gaffin, EVP and chief legal officer, sold 2,034 ordinary shares on Aug. 3, 2026 at USD 48.58.His direct stake fell t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL9zXC08:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSIL","MEDX","ALKS","PSCH","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300873","title":"Dianthus Therapeutics Inc Expected to Post a Loss of 86 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300873","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300873?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:12","pubTimestamp":1785795140,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics Inc <DNTH.OQ> expected to post a loss of86cents a share - Earnings PreviewDianthus Therapeutics IncDNTH.OQDNTH.Ois expected to  show a rise in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656062307","title":"Dianthus Therapeutics Grants 87,000 Inducement Stock Options at $106.02 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2656062307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656062307?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:00","pubTimestamp":1785794413,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics grants 87,000 inducement stock options at $106.02 per shareDianthus Therapeutics granted inducement equity awards on Aug. 3, 2026 to six newly hired non-executive employees.Non-q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3J16cY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","SG9999014005.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BKPKM429.USD","LU2210149790.SGD","DNTH","LU2210150020.SGD","BCDF","SG9999014013.SGD","BK4588","SG9999014021.USD","IBRN","IE00BGHQF748.EUR","IE00BN0W2W23.USD","SG9999014039.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4112","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036307","title":"Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036307?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:00","pubTimestamp":1785794400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA59RRJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656019363","title":"Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2656019363","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656019363?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:09","pubTimestamp":1785787780,"startTime":"0","endTime":"0","summary":"Alkermes amends 8-K to disclose CEO Blair Jackson pay package including $5 million equity awardAlkermes amended a Feb. 25 Form 8-K on its CEO succession to add previously undetermined compensation ter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL2dlwWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSIL","IBRN","PSCH","FBT","BK4139","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303694","title":"Praxis Extends Vormatrogine Epilepsy Trial, Keeping Long-Term Growth Story in Play","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303694","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303694?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:32","pubTimestamp":1785774777,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. ($PRAX) announced an update on their ongoing clinical study. Praxis Precision Medicines is running an extension st...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-extends-vormatrogine-epilepsy-trial-keeping-long-term-growth-story-in-play?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-extends-vormatrogine-epilepsy-trial-keeping-long-term-growth-story-in-play?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","IBRN","IE0009355771.USD","PRAX","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656036353","title":"Praxis Advances PRAX-628 Tablet Formulation in Completed Bioavailability Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656036353","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656036353?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:30","pubTimestamp":1785774621,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. ($PRAX) announced an update on their ongoing clinical study. Praxis PRAX-628 Trial Shows Progress on Next-Gen Epil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-advances-prax-628-tablet-formulation-in-completed-bioavailability-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-advances-prax-628-tablet-formulation-in-completed-bioavailability-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","PRAX","IBRN","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182656115","title":"Stairway Medical Achieves Key Breakthroughs in Implantable Brain-Computer Interfaces, Helping Multiple High-Level Quadriplegics Return to the Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=1182656115","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182656115?lang=en_us&edition=fundamental","pubTime":"2026-08-01 18:50","pubTimestamp":1785581436,"startTime":"0","endTime":"0","summary":"Shanghai Stairway Medical Technology Co., Ltd. (referred to as Stairway Medical) announced that its self-developed minimally invasive implantable brain-computer interface technology has enabled...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159891","IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167091597","title":"Good Morning Anhui: Province Records First-Ever Brain-Computer Interface Prescription and Successful Surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=1167091597","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167091597?lang=en_us&edition=fundamental","pubTime":"2026-08-01 08:30","pubTimestamp":1785544243,"startTime":"0","endTime":"0","summary":"On the evening of July 27, the Hongcun Ancient Village scenic area in Yixian County was brightly lit, with numerous tourists enjoying a leisurely visit. With the arrival of the summer tourism season,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656585399","title":"Xenon Pharma Grants 32,758 Inducement Stock Options, 19,013 RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2656585399","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656585399?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528080,"startTime":"0","endTime":"0","summary":"Xenon Pharma grants 32,758 inducement stock options, 19,013 RSUs to new hiresXenon Pharmaceuticals granted inducement equity awards to 11 new non-officer employees, totaling 32,758 share options and 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDLbfcL3N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","BK4112","XENE","LU2095319765.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","SBIO","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4139","IBRN","BCDF","BK4588","LU2210149790.SGD","BK4585","NDAQ","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399370","title":"Xenon Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399370?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUA7BSC6X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391209","title":"Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391209?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:01","pubTimestamp":1785528060,"startTime":"0","endTime":"0","summary":"VANCOUVER, BC and BOSTON, MA, July  31, 2026  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical deve","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/31/3337042/33485/en/Xenon-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4139","IBRN","XENE","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179761802","title":"Multiple New National Standards to Take Effect Starting August 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1179761802","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179761802?lang=en_us&edition=fundamental","pubTime":"2026-07-31 14:41","pubTimestamp":1785480080,"startTime":"0","endTime":"0","summary":"Starting August 1, 46 mandatory national standards and 442 recommended national standards will come into effect. These include key standards for energy consumption limits of related products, water...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IVRS","CTEX","IBRN","ICLN","MAKX","PBW","BK4596","MNTL","TAN","BK4020","RAYS","BK4585","GNSS","ACES","ARVR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126900244","title":"Key to Brain-Computer Interfaces Found Through Large AI Models","url":"https://stock-news.laohu8.com/highlight/detail?id=1126900244","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126900244?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:24","pubTimestamp":1785414269,"startTime":"0","endTime":"0","summary":"A newly launched neural AI company, Hemispheric, co-founded by Gideon Litwin, the co-inventor of Apple's Face ID and Vision Pro technologies, has introduced a massive AI brainwave model called...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNTL","LRNZ","EPAI","WISE","GPTZ","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655926538","title":"Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655926538","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655926538?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:53","pubTimestamp":1785340439,"startTime":"0","endTime":"0","summary":"Alkermes'  base business supported the company's Q2 beat, while its orexin pipeline serves as a potential catalyst for future revenue growth, RBC Capital Markets said in a Tuesday note.The company reported a breakeven in Q2, compared with earnings of $0.52 per share a year earlier, and revenue of $496 million, up from $390.7 million. For 2026, Alkermes reiterated its total revenue guidance of $1.73 billion to $1.84 billion.Alkermes' core business drove the quarter's revenue beat, with recent highlights like less generic threat for Vivitrol and expanded access for Lybalvi, RBC said. The quarter also said one-time benefits from patient mix favorability, Lumryz inventory and Consta manufacturing, the brokerage added.Looking forward, investor focus is shifting to the company's orexin pipeline expansion into other indications, which could help pave the way for Alkermes's revenue to exceed $5 billion, RBC noted.RBC has an outperform rating and $56 price target on Alkermes.Price: 48.40, Chang","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MEDX","PSCH","IBRN","BK4139","ALKS","PSIL","FBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}